Bringing patients into focus
with ocular gene therapy

ATSENA THERAPEUTICS is conducting clinical trials evaluating investigational gene therapies for inherited retinal diseases. Our two active clinical programs are ATSN-201 for X-linked retinoschisis (XLRS) and ATSN-101 for Leber congenital amaurosis type 1 (LCA1). Participation in Atsena’s clinical trials is currently the only pathway for patients to access our investigational therapies.

XLRS Trial

ATSN-201: Phase I/II/III (LIGHTHOUSE trial)
ClinicalTrials.gov Identifier: NCT05878860
Status: Active and recruiting
Learn more about the clinical trial here.

LCA1

ATSN-101: Phase I/II
ClinicalTrials.gov Identifier: NCT03920007
Status: Active, no longer recruiting
Learn more about the clinical trial here.

Contact

Contact us with questions at [email protected]

All of Atsena’s gene therapy products are investigational. Safety and efficacy have not been established by the FDA or other regulatory bodies. Participation in Atsena Therapeutics’ clinical trials is currently the only pathway for patients to gain access to our investigational therapies. Atsena does not offer compassionate use or expanded access programs at this time.